Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

36.52 -1.81 (-4.72%)
Streaming Delayed Price Updated: 10:28 AM EST, Dec 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NewAmsterdam Pharma Company N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
Enrollment to continue to the end of April to accommodate strong patient and site interest 
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
World Acceptance Posts Upbeat Earnings, Joins Kaman, Spirit Airlines And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of World Acceptance Corporation (NASDAQ: WRLD) rose sharply during Friday’s session following upbeat... 
Via Benzinga
Topics Stocks
News headline image
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode... 
Via Benzinga
News headline image
Cholesterol Player NewAmsterdam Pharma's Obicetrapib Is A Potential Blockbuster In Cardiovascular Market: Bullish Analyst Says ↗
Piper Sandler's coverage on NewAmsterdam Pharma and its clinical-stage therapy, Obicetrapib, a potent CETP inhibitor targeting cardiovascular health. With a unique mechanism, superior efficacy, and... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results. 
Via Benzinga
News headline image
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces 2024 Strategic Priorities
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
FMC, Li-Cycle Holdings, Okta And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction. 
Via Benzinga
News headline image
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
From NewAmsterdam Pharma N.V
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.